

NMSS:JEW
Control No. 460793

FEB 19 1987

Memorial Hospital of Carbon County
ATTN: Richard H. Mills
Executive Director
2221 West Elm
Rawlins, Wyoming 82301

Gentlemen:

This is in reference to your request for a byproduct material license renewal dated October 16, 1986, and letter dated December 18, 1986, in the name of Memorial Hospital of Carbon County. In order for us to complete our review of your request, please supply the following:

1. In your application dated October 16, 1986, you requested that Memorial Hospital of Carbon County be authorized to use Group IV and V radiopharmaceuticals. To be authorized for Groups IV and V materials it will be necessary to have listed on your license a user who is qualified by training and experience to use those materials. Your only authorized user, James P. Dyrud, D.O., has not submitted sufficient information to be authorized for these additional groups. Should Dr. Dyrud wish to be authorized for these additional groups or individual items in Groups IV and V, he should provide evidence of his equivalent training to that outlined in Appendix A of Regulatory Guide 10.8. This evidence of training and experience should be provided on a dated and signed preceptor statement, NRC Form 313M-Supplement B. As the application currently stands, we can authorize your institution for the use of iodine-131 for treatment of hyperthyroidism, cardiac dysfunction, or thyroid carcinoma, provided the concerns addressed in this letter are adequately covered.
2. Your application indicates that you may open an dispense millicurie quantities of iodine-131 as liquid sodium iodide. In accordance with 10 CFR 20.1(c), you should maintain releases of iodine-131 to the environment well below the applicable limits specified in 10 CFR 20.106. (As a guideline, we use 10 percent of the limits specified in Section 20.106.). Most licensees use charcoal filtration systems to achieve this goal.

Submit a detailed description of the charcoal filtration system (or equivalent system) that you will employ. Indicate the percentage of iodine 131 that this system may be expected to remove from environmental effluents.

RIV:NMSS
JEW:atten;df
2/13/87

C:NMSS
RJE:erett
2/15/87

8708210278 870422
REG4 LIC30
49-19237-01 PDR

3. Thyroid uptake can occur by breathing volatile iodine which is released when the cap is first removed from vials containing therapeutic liquid iodine-131. Personnel should be instructed to wear gloves and to open the vials in a fume hood or to take alternative precautionary measures.

A bioassay program should be established for personnel who handle therapeutic liquid iodine-131. As a minimum, thyroid counts should be obtained approximately 24 hours after exposure. Refer to the enclosed bioassay guide.

Submit the precautionary measures and the bioassay procedures that you will follow.

In order to continue prompt review of your application, we request that you submit your response to this letter within 30 calendar days from the date of this letter.

Please reply in duplicate and refer to Control No. 460793.

Sincerely,

Original signed by
JACK E. WHITTEN

Jack E. Whitten
Nuclear Materials Safety Section

Enclosures:

1. Regulatory Guide 10.8
2. Regulatory Guide 8.20
3. 10 CFR 19
4. 10 CFR 20
5. 10 CFR 35

bcc w/o enclosures:
R. L. Bangart